More on ENTA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+41.2% Growth)
- Ratings (7.9 Score)
- Holders
- FDA Archive

Upcoming Events

- Earnings (8/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Enanta Pharma (NQ:ENTA)
Delayed: 12.95 -0.11 (0.84%)
Prev. Close $13.06  
Open$12.87 
52 Wk High$34.49 
52 Wk Low$20.39 
Day High$13.09 
Day Low$12.52 
P/E N/A  
EPS$-3.18 
Volume129,271 

Friends, Peers and Foes (?): RNTX WVE (more...)

Jul 2, 2026 04:58 PM Enanta Pharmaceuticals sets up $75M at-the-market stock offering
Jul 2, 2026 04:57 PM Form 8-K ENANTA PHARMACEUTICALS For: Jul 02
Jul 2, 2026 04:54 PM Form 424B5 ENANTA PHARMACEUTICALS
Jun 23, 2026 05:30 PM Enanta Pharma loses appeal in Pfizer Paxlovid patent case
Jun 23, 2026 05:28 PM Form 8-K ENANTA PHARMACEUTICALS For: Jun 23
Jun 23, 2026 06:52 AM H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)
Jun 23, 2026 05:10 AM Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Jun 18, 2026 07:13 AM Form 8-K ENANTA PHARMACEUTICALS For: Jun 18
Jun 18, 2026 07:01 AM Enanta advances RSV drug zelicapavir into late-stage trials
Jun 18, 2026 07:00 AM Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
View All Articles

Entities mentioned with ENTA

View All Entities